IQVIA gets CDSCO panel okay to reopen trial recruitment in the country for Evobrutinib
New Delhi: Approving IQVIA proposal to amend Phase III Clinical Trail protocol of Bruton's tyrosine kinase (BTK) inhibitor Evobrutinib, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended for the reopening of the trial recruitment in the country with the proposed protocol amendment.This recommendation came after the firm...
New Delhi: Approving IQVIA proposal to amend Phase III Clinical Trail protocol of Bruton's tyrosine kinase (BTK) inhibitor Evobrutinib, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended for the reopening of the trial recruitment in the country with the proposed protocol amendment.
Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd